Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies

Role of PAI-1 in hepatic steatosis and dyslipidemia

(2021) Joshua A. Levine et al.   Scientific Reports

Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol

(2019) Stefano Spolitu et al.   CIRCULATION RESEARCH

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

(2019) Lea C. Berkhout et al.   Science Translational Medicine

The PCSK9 revolution: Current status, controversies, and future directions

(2019) Bruce A. Warden et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

(2019) Jennifer G. Robinson et al.   Journal of Clinical Lipidology

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

(2018) Michael D. Shapiro et al.   ANNALS OF INTERNAL MEDICINE

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

(2018) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond

(2018) Russell A. DeBose-Boyd et al.   TRENDS IN BIOCHEMICAL SCIENCES

Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations

(2018) Chen Wang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake

(2018) Adri M. Galvan et al.   JOURNAL OF LIPID RESEARCH

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis

(2017) E Berthold et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

(2017) Camilla Gustafsen et al.   Nature Communications

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis

(2016) Robin Kahn et al.   ACTA PAEDIATRICA

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective

(2016) Gerald F. Watts et al.   CIRCULATION

The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation

(2016) Delia Susan-Resiga et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

(2016) John P. Gibbs et al.   JOURNAL OF CLINICAL PHARMACOLOGY

On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects

(2015) Hagai Tavori et al.   ATHEROSCLEROSIS

The Agenda for Familial Hypercholesterolemia

(2015) Samuel S. Gidding et al.   CIRCULATION

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

(2015) John S. Millar et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

(2015) Michael J. Koren et al.   POSTGRADUATE MEDICINE

The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion

(2014) Camilla Gustafsen et al.   Cell Metabolism

Practical Immunoaffinity-Enrichment LC-MS for Measuring Protein Kinetics of Low-Abundance Proteins

(2014) M. E. Lassman et al.   CLINICAL CHEMISTRY

PCSK9 and LDLR degradation

(2014) Thomas A. Lagace   CURRENT OPINION IN LIPIDOLOGY

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-αand Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

(2014) Martin Schulz et al.   Biomed Research International

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor

(2013) Hagai Tavori et al.   CIRCULATION

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

(2012) Liwen Zhang et al.   International Journal of Biological Sciences

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways

(2012) Jamie Cameron et al.   Translational Research

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

(2009) Christopher J. Duff et al.   BIOCHEMICAL JOURNAL

Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†

(2008) Daping Fan et al.   BIOCHEMISTRY

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH